Home > Articles > SIRT3 and mitochondrial NAD+: the deacetylase inside mitochondria
SIRT3 and mitochondrial NAD+: the deacetylase inside mitochondria
Prepared by: Research Desk
Prepared by: Research Desk. Sources are linked for verification.
SIRT3 is the sirtuin most often named in discussions of mitochondria. It is an enzyme that removes acetyl groups from proteins inside the mitochondrial matrix, and it cannot do that without NAD+. This explainer covers where SIRT3 sits, the chemistry of the reaction, which pathways it has been linked to, and what genetically modified mice and cell models have reported. For the wider sirtuin family, see our companion page on NAD+ and sirtuins. For the overall map of NAD+ biochemistry, start with the NAD+ guide.
Where SIRT3 sits in the cell
Mammals have seven sirtuins, SIRT1 to SIRT7. They are split by location. SIRT1 and SIRT2 are found in the nucleus and cytoplasm. SIRT6 and SIRT7 are nuclear. SIRT3, SIRT4 and SIRT5 are localised in mitochondria [1]. A review of the mitochondrial sirtuins places all three within the mitochondrial matrix, the inner compartment where the tricarboxylic acid (TCA) cycle and fatty acid oxidation take place [2].
The three mitochondrial sirtuins do not do the same job. SIRT3 and SIRT5 are described as NAD+-dependent deacetylases. SIRT4 can instead transfer an ADP-ribose group from NAD+ onto acceptor proteins [2]. Of the three, SIRT3 is the one repeatedly described as the main mitochondrial sirtuin, because clusters of its protein substrates have been identified in mitochondria [3]. A 2024 review calls it "the major protein deacetylase of mitochondria" [4].
The reaction: what SIRT3 does with NAD+
Many mitochondrial proteins carry acetyl groups attached to lysine residues. According to the mitochondrial sirtuin review, a large fraction of mitochondrial proteins are acetylated, and the level of acetylation shifts with nutritional status [2].
SIRT3 removes those acetyl groups. The reaction does not simply borrow NAD+ and give it back. SIRT3 and SIRT5 take an acetyl-lysine protein plus NAD+ and yield a deacetylated protein, 2'-O-acetyl-ADP-ribose and nicotinamide [2]. NAD+ is split in the process. That makes SIRT3 an NAD+ consumer, in the same broad category as the PARP enzymes and CD38, rather than a redox carrier that cycles between NAD+ and NADH.
Two consequences follow from that chemistry:
The nicotinamide has to be recycled. The nicotinamide released by sirtuins feeds back into the NAD+ salvage pathway, which rebuilds NAD+.
Activity depends on NAD+ availability. Because sirtuins need NAD+ to work, their activity is thought to reflect the redox and energy status of the cell. One review describes them as "bona fide metabolic stress sensors" for this reason [3]. The balance between oxidised and reduced forms is covered in our NAD+/NADH ratio explainer.
Reviewers describe SIRT3 as a nutrient sensor whose activity rises under conditions of mild metabolic stress [4]. The mitochondrial sirtuin review frames SIRT3, SIRT4 and SIRT5 together as metabolic sensors that adjust the activity of metabolic enzymes by deacetylation or mono-ADP-ribosylation [2].
What SIRT3 has been linked to
The list of reported SIRT3 targets is long, and most of it comes from cell and animal work. A 2024 review states that within mitochondria SIRT3 regulates every complex of the electron transport chain, the TCA and urea cycles, the mitochondrial membrane potential and free radical scavengers. The same review discusses SIRT3 in relation to reactive oxygen species, ATP, immune function and mitochondrial dynamics [4].
Other reviews connect SIRT3 to oxidative stress, inflammation, DNA damage and apoptosis [5]. Research has also asked what controls SIRT3 itself. One study reported that SENP1-Sirt3 signalling controls mitochondrial protein acetylation and metabolism [6]. That points to SIRT3 as one node in a regulatory network, not a stand-alone switch.
Knockout and overexpression findings
Genetic models are the main tool researchers use to ask what happens when SIRT3 is missing or more abundant. Several examples in the published literature:
Blood vessels (mouse and human tissue). A review from a group studying hypertension reports that genetic deletion of Sirt3 in mice promotes vascular dysfunction and hypertension, and that Sirt3 depletion promotes endothelial dysfunction. The same authors report that people with essential hypertension had decreased Sirt3 levels, with hyperacetylation of mitochondrial proteins [7]. The human finding is an association. The causal direction is inferred from the mouse knockout.
Liver. A review of SIRT3 in liver fibrosis summarises its roles in the main liver cell types, including hepatocytes and hepatic stellate cells, the cells whose activation drives extracellular matrix deposition [5].
Brain models. A review on neurodegenerative disorders notes findings that SIRT3 overexpression could prevent neuronal derangements in certain in vivo and in vitro models of aging and neurodegeneration, including Alzheimer's disease models [3]. A 2025 study reports that SIRT3-mediated deacetylation of the mitochondrial fission protein DRP1 at lysine K711 prevents mitochondrial dysfunction in experimental Parkinson's disease work [8].
Cancer. Sirtuins have been reported to play roles in both suppression and progression of human cancers. A 2024 review discusses small-molecule activators and inhibitors of sirtuins as research tools and drug candidates [1]. A mitochondrial sirtuin that can push in either direction depending on context is a reminder that "more SIRT3" is not a simple goal.
How to read SIRT3 claims
Claim type | Typical evidence | What it can support |
|---|---|---|
SIRT3 deacetylates protein X | Cell and biochemical assays | Mechanism in that system |
Sirt3 knockout mice develop phenotype Y | Mouse genetics | Requirement for SIRT3 in mice |
Lower SIRT3 in people with condition Z | Human tissue measurement | Association only |
A product "activates SIRT3" | Usually none in humans | Not established |
None of the sources above measured SIRT3 activity in living humans in response to an NAD+ precursor. For how NAD+ products are classified and what labels can legally say, see our page on U.S. rules for NMN, NR and IV NAD+. Our sourcing and evidence-labelling approach is described on the about page.
Choosing a biochemistry book for this topic
SIRT3 sits at the crossroads of enzyme kinetics, mitochondrial metabolism and protein modification. A good general biochemistry text makes the primary papers far easier to follow. When comparing books, these neutral criteria are the ones that matter:
Edition date. Mitochondrial acetylation became a major research theme relatively recently, so older editions may barely mention sirtuins.
Pathway figures. Look for clear diagrams of the TCA cycle, electron transport chain and urea cycle, the pathways most often tied to SIRT3.
Post-translational modification coverage. A dedicated section on lysine acetylation and NAD+-consuming enzymes is a strong sign of depth.
References. Chapters that cite primary literature let readers check claims rather than take them on trust.
Format and price transparency. Compare print, e-book and rental options, and check whether companion figures or problem sets carry extra cost.
For a graded list focused on sirtuins and aging, see our NAD+ reading list.
Further reading
The slot below is reserved for general biochemistry and mitochondrial metabolism textbooks chosen on the criteria above.
Frequently asked questions
Is SIRT3 the only sirtuin in mitochondria?
No. SIRT3, SIRT4 and SIRT5 are all located in the mitochondrial matrix [2]. SIRT3 is described as the major mitochondrial deacetylase, while SIRT4 transfers ADP-ribose and SIRT5 is another NAD+-dependent deacetylase [2][4].
Does SIRT3 use up NAD+?
Yes. Its deacetylation reaction splits NAD+ into nicotinamide and 2'-O-acetyl-ADP-ribose [2]. The nicotinamide can be recycled into NAD+ through the salvage pathway.
Do NAD+ precursors raise SIRT3 activity in people?
That has not been shown in the sources reviewed here. A human trial of nicotinamide riboside reported that it elevated NAD+ in healthy middle-aged and older adults [9], but raising NAD+ is not the same as measuring SIRT3 activity in human mitochondria.
Why are knockout mice so central to SIRT3 research?
Deleting the gene shows what the enzyme is required for in a living animal. Examples include the vascular dysfunction and hypertension reported in Sirt3-deficient mice [7]. Mouse findings still need separate confirmation in humans.
Related on this site
NAD+ and sirtuins: how the enzymes use NAD+ and what research examined
NAD+ explained: biochemistry, precursors, testing and human evidence
CD38 and NAD+ decline: what enzyme and mouse knockout studies show
The NAD+/NADH ratio explained: redox balance and how it is measured
Last updated: 26 October 2026.
Not medical advice. This page reports published research and regulatory records for information only.
Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.
Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.